{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:48:54Z","timestamp":1792032534373,"version":"4.4.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"European Organization for Research and Treatment of Cancer"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Myelosuppression is the major toxicity encountered during temozolomide chemoradiotherapy for newly diagnosed glioblastoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We assessed the association of myelosuppression (neutropenia, thrombocytopenia, anemia, and lymphopenia) during temozolomide chemoradiotherapy alone or in combination with experimental agents with progression-free survival (PFS) or overall survival (OS) in 2073 patients with newly diagnosed glioblastoma enrolled into five clinical trials: CENTRIC, CORE, EORTC 26082, AVAglio, and EORTC 26981. A landmark Cox model was used. For each primary association analysis, a significance level of 1.7% was used.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Lower neutrophil counts at baseline were associated with better PFS (P = .011) and OS (P &amp;lt; .001), independently of steroid intake. Females experienced uniformly more myelotoxicity than males. Lymphopenia during concomitant chemoradiotherapy was associated with OS (P = .009): low-grade (1-2) lymphopenia might be associated with superior OS (HR 0.78, 98.3% CI 0.58\u20131.06), whereas high-grade (3-4) lymphopenia might be associated with inferior OS (HR 1.08, 98.3% CI 0.75\u20131.54). There were no associations of altered hematological parameters during concomitant chemoradiotherapy with PFS. During maintenance chemoradiotherapy, no significant association was found between any parameter of myelosuppression and PFS or OS, although exploratory analysis at 5% significance level indicated that either mild-to-moderate (HR 0.76, 95% CI 0.62\u20130.93) or high-grade lymphopenia (HR 0.65, 95% CI 0.46\u20130.92) was associated with superior OS (P = .013), but not PFS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The association of higher neutrophil counts at baseline with inferior PFS and OS requires further prospective evaluation. The link of therapy-induced lymphopenia to better outcome may guide the design for immunotherapy trials in newly diagnosed glioblastoma.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/neuonc\/noac070","type":"journal-article","created":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T12:07:01Z","timestamp":1647778021000},"page":"1533-1545","source":"Crossref","is-referenced-by-count":33,"title":["Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma"],"prefix":"10.1093","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9408-3278","authenticated-orcid":false,"given":"Emilie","family":"Le Rhun","sequence":"first","affiliation":[{"name":"Departments of Neurosurgery and Neurology & Brain Tumor Center, University Hospital and University of Zurich , Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix Boakye","family":"Oppong","sequence":"additional","affiliation":[{"name":"EORTC Headquarters , Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Vanlancker","sequence":"additional","affiliation":[{"name":"EORTC Headquarters , Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5483-3118","authenticated-orcid":false,"given":"Roger","family":"Stupp","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire Vaudois and University of Lausanne , Lausanne , Switzerland"},{"name":"Malnati Brain Tumor Center of the Lurie Comprehensive Cancer Center and Departments of Neursurgery and Neurology, Northwestern University Feinberg School of Medicine , Chicago, IL 60611 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burt","family":"Nabors","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Neuro-Oncology, University of Alabama at Birmingham , Birmingham, AL 35294 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chinot","sequence":"additional","affiliation":[{"name":"Aix-Marseille University, AP-HM, Service de Neuro-Oncologie , CHU Timone, Marseille , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6171-634X","authenticated-orcid":false,"given":"Wolfgang","family":"Wick","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neuro-oncology Program at the National Center for Tumor Diseases, University Hospital Heidelberg and German Cancer Research Center , Heidelberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3541-2315","authenticated-orcid":false,"given":"Matthias","family":"Preusser","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Division of Oncology, Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Gorlia","sequence":"additional","affiliation":[{"name":"EORTC Headquarters , Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-174X","authenticated-orcid":false,"given":"Michael","family":"Weller","sequence":"additional","affiliation":[{"name":"Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich , Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"issue":"10","key":"2022090114013596100_CIT0001","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"issue":"3","key":"2022090114013596100_CIT0002","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol."},{"issue":"5","key":"2022090114013596100_CIT0003","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"issue":"10","key":"2022090114013596100_CIT0004","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med."},{"issue":"1","key":"2022090114013596100_CIT0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1215\/15228517-2006-024","article-title":"The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas","volume":"9","author":"Gerber","year":"2007","journal-title":"Neuro-oncology"},{"issue":"6","key":"2022090114013596100_CIT0006","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1215\/15228517-2008-120","article-title":"Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors","volume":"11","author":"Armstrong","year":"2009","journal-title":"Neuro-oncology"},{"issue":"5","key":"2022090114013596100_CIT0007","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/COC.0b013e3182a790ea","article-title":"Clinical and genetic factors associated with severe hematological toxicity in glioblastoma patients during radiation plus temozolomide treatment: a prospective study","volume":"38","author":"Lombardi","year":"2015","journal-title":"Am J Clin Oncol."},{"issue":"8","key":"2022090114013596100_CIT0008","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"22","author":"Wen","year":"2020","journal-title":"Neuro Oncol."},{"issue":"2","key":"2022090114013596100_CIT0009","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10143-017-0903-3","article-title":"Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients","volume":"41","author":"Saito","year":"2018","journal-title":"Neurosurg Rev."},{"issue":"1","key":"2022090114013596100_CIT0010","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3171\/2016.7.JNS16609","article-title":"Bone marrow response as a potential biomarker of outcomes in glioblastoma patients","volume":"127","author":"Vaios","year":"2017","journal-title":"J Neurosurg."},{"issue":"10","key":"2022090114013596100_CIT0011","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.6004\/jnccn.2015.0151","article-title":"Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors","volume":"13","author":"Grossman","year":"2015","journal-title":"J Natl Compr Canc Netw."},{"issue":"16","key":"2022090114013596100_CIT0012","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1158\/1078-0432.CCR-11-0774","article-title":"Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide","volume":"17","author":"Grossman","year":"2011","journal-title":"Clin Cancer Res."},{"issue":"10","key":"2022090114013596100_CIT0013","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial","volume":"15","author":"Stupp","year":"2014","journal-title":"Lancet Oncol."},{"issue":"5","key":"2022090114013596100_CIT0014","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/neuonc\/nou356","article-title":"Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study","volume":"17","author":"Nabors","year":"2015","journal-title":"Neuro-oncology"},{"issue":"19","key":"2022090114013596100_CIT0015","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-15-3153","article-title":"Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082)","volume":"22","author":"Wick","year":"2016","journal-title":"Clin Cancer Res."},{"issue":"8","key":"2022090114013596100_CIT0016","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med."},{"issue":"2","key":"2022090114013596100_CIT0017","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s12350-019-01624-z","article-title":"Landmark analysis: a primer","volume":"26","author":"Morgan","year":"2019","journal-title":"J Nucl Cardiol."},{"issue":"2","key":"2022090114013596100_CIT0018","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s12561-016-9157-9","article-title":"Understanding landmarking and its relation with time-dependent Cox regression","volume":"9","author":"Putter","year":"2017","journal-title":"Stat Biosci."},{"key":"2022090114013596100_CIT0019","doi-asserted-by":"crossref","DOI":"10.1201\/b16248","volume-title":"Handbook of Survival Analysis","author":"Klein","year":"2016"},{"key":"2022090114013596100_CIT0020","doi-asserted-by":"crossref","DOI":"10.1201\/b18041","volume-title":"Modelling Survival Data in Medical Research","author":"Collett","year":"2015"},{"issue":"Pt 5","key":"2022090114013596100_CIT0021","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/brain\/aww046","article-title":"Corticosteroids compromise survival in glioblastoma","volume":"139","author":"Pitter","year":"2016","journal-title":"Brain"},{"key":"2022090114013596100_CIT0022","doi-asserted-by":"crossref","first-page":"580101","DOI":"10.3389\/fneur.2020.580101","article-title":"Systemic inflammatory indicators as prognosticators in glioblastoma patients: a comprehensive meta-analysis","volume":"11","author":"Yang","year":"2020","journal-title":"Front Neurol."},{"key":"2022090114013596100_CIT0023","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ctro.2018.04.002","article-title":"Neutrophilia as a biomarker for overall survival in newly diagnosed high-grade glioma patients undergoing chemoradiation","volume":"10","author":"Schernberg","year":"2018","journal-title":"Clin Transl Radiat Oncol."},{"issue":"19","key":"2022090114013596100_CIT0024","doi-asserted-by":"crossref","first-page":"e1799","DOI":"10.1212\/WNL.0000000000008440","article-title":"Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: the PLATUM trial","volume":"93","author":"Le Rhun","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"2022090114013596100_CIT0025","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11060-020-03598-2","article-title":"Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor","volume":"151","author":"Hotchkiss","year":"2021","journal-title":"J Neurooncol."},{"issue":"4","key":"2022090114013596100_CIT0026","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1200\/JCO.2004.07.060","article-title":"Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications","volume":"22","author":"Su","year":"2004","journal-title":"J Clin Oncol."},{"issue":"2","key":"2022090114013596100_CIT0027","doi-asserted-by":"crossref","first-page":"e23288","DOI":"10.4161\/onci.23288","article-title":"Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients","volume":"2","author":"Iversen","year":"2013","journal-title":"Oncoimmunology"},{"issue":"3","key":"2022090114013596100_CIT0028","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/neuonc\/noq157","article-title":"Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma","volume":"13","author":"Sampson","year":"2011","journal-title":"Neuro Oncol."},{"issue":"3","key":"2022090114013596100_CIT0029","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11060-017-2395-y","article-title":"Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival","volume":"132","author":"Mason","year":"2017","journal-title":"J Neurooncol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noac070\/43387196\/noac070.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/24\/9\/1533\/45639283\/noac070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/24\/9\/1533\/45639283\/noac070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T15:03:25Z","timestamp":1662044605000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/24\/9\/1533\/6551573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,3,21]]},"published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noac070","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2022,3,21]]}}}